FindTrial
Sign In

An Open Label Extension Study of Phase III Clinical Trial of Duloxetine in Patients With Fibromyalgia

An Open Label Extension Study of Phase III Clinical Trial of Duloxetine in Patients With Fibromyalgia

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221803
Enrollment
Unknown
Registered
2012-05-29
Start date
2012-05-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Interventions

investigational material(s) Generic name etc : Duloxetine Hydrochloride INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Admi

Sponsors

SHIONOGI & CO., LTD.
Lead Sponsor
Eli Lilly and Company
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Participants who have completed the 15-week treatment in the preceding study (A Phase III clinical trial of duloxetine in participants with fibromyalgia), etc.

Exclusion criteria

Exclusion criteria: Participants with pain caused by diseases other than fibromyalgia and which possibly has any effect to the assessment, etc.

Design outcomes

Primary

MeasureTime frame
The incidence of both adverse events and adverse drug reactions—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026